Form 4: Cytek Biosciences Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Glenn P. Muir was granted 55,555 restricted stock units and 29,835 stock options by Cytek Biosciences.
Summary
- Director Glenn P. Muir received a grant of 55,555 restricted stock units (RSUs) on June 10, 2026.
- Director Glenn P. Muir received a grant of 29,835 stock options with an exercise price of $4.05 on June 10, 2026.
- The RSU award vests over a multi-year schedule beginning August 18, 2026.
- The stock options vest monthly over a three-year period starting from the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the vesting and exercise of these equity awards.
Risks
- Market volatility affecting the value of equity compensation.
- Performance-based vesting risks associated with the company's future stock price and operational success.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members are incentivized to drive long-term company performance.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director equity is consistent with standard corporate governance practices for NASDAQ-listed life sciences companies.
Stakeholder Impact
- Minor dilution impact on existing shareholders upon future exercise of options and vesting of RSUs.
Next Steps
- Vesting of RSU awards beginning August 18, 2026.
- Monthly vesting of stock options over the next three years.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of grant for RSUs and stock options. |
| 06/12/2026 | Date of filing. |
| 08/18/2026 | Initial vesting date for a portion of the RSU award. |
| 06/10/2036 | Expiration date for the stock options. |
Keywords
Cytek Biosciences, CTKB, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.